154 related articles for article (PubMed ID: 37160628)
1. Systematic analysis of transcriptome signature for improving outcomes in lung adenocarcinoma.
Ge X; Xu H; Weng S; Zhang Y; Liu L; Wang L; Xing Z; Ba Y; Liu S; Li L; Wang Y; Han X
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8951-8968. PubMed ID: 37160628
[TBL] [Abstract][Full Text] [Related]
2. Identification of disulfidptosis-related subgroups and prognostic signatures in lung adenocarcinoma using machine learning and experimental validation.
Wang Y; Xu Y; Liu C; Yuan C; Zhang Y
Front Immunol; 2023; 14():1233260. PubMed ID: 37799714
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of an immune-related prognostic signature in lung adenocarcinoma.
Sun S; Guo W; Wang Z; Wang X; Zhang G; Zhang H; Li R; Gao Y; Qiu B; Tan F; Gao Y; Xue Q; Gao S; He J
Cancer Med; 2020 Aug; 9(16):5960-5975. PubMed ID: 32592319
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
5. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
7. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis and Reinforcement Learning of Hypoxic Genes Based on Four Machine Learning Algorithms for Estimating the Immune Landscape, Clinical Outcomes, and Therapeutic Implications in Patients With Lung Adenocarcinoma.
Sun Z; Zeng Y; Yuan T; Chen X; Wang H; Ma X
Front Immunol; 2022; 13():906889. PubMed ID: 35757722
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
10. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Wang J; Zhan X
Front Immunol; 2021; 12():752643. PubMed ID: 34887858
[TBL] [Abstract][Full Text] [Related]
11. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
12. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients.
Shi R; Bao X; Unger K; Sun J; Lu S; Manapov F; Wang X; Belka C; Li M
Theranostics; 2021; 11(10):5061-5076. PubMed ID: 33754044
[No Abstract] [Full Text] [Related]
14. Integrating multiple machine learning methods to construct glutamine metabolism-related signatures in lung adenocarcinoma.
Zhang P; Pei S; Wu L; Xia Z; Wang Q; Huang X; Li Z; Xie J; Du M; Lin H
Front Endocrinol (Lausanne); 2023; 14():1196372. PubMed ID: 37265698
[TBL] [Abstract][Full Text] [Related]
15. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
Li F; Niu Y; Zhao W; Yan C; Qi Y
Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
[TBL] [Abstract][Full Text] [Related]
16. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
Chen G; Dong Z; Wu D; Chen Y
J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
[TBL] [Abstract][Full Text] [Related]
17. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
18. Systematic integration of machine learning algorithms to develop immune escape-related signatures to improve clinical outcomes in lung adenocarcinoma patients.
Wang T; Huang L; Zhou J; Li L
Front Immunol; 2023; 14():1131768. PubMed ID: 36936970
[TBL] [Abstract][Full Text] [Related]
19. A Machine-Learning Approach to Developing a Predictive Signature Based on Transcriptome Profiling of Ground-Glass Opacities for Accurate Classification and Exploring the Immune Microenvironment of Early-Stage LUAD.
Zhao Z; Yin W; Peng X; Cai Q; He B; Shi S; Peng W; Tu G; Li Y; Li D; Tao Y; Peng M; Wang X; Yu F
Front Immunol; 2022; 13():872387. PubMed ID: 35693786
[TBL] [Abstract][Full Text] [Related]
20. Systematic Analyses of a Chemokine Family-Based Risk Model Predicting Clinical Outcome and Immunotherapy Response in Lung Adenocarcinoma.
Chen J; Liu X; Wu Q; Jiang X; Zeng Z; Li J; Gao Y; Gong Y; Xie C
Cell Transplant; 2021; 30():9636897211055046. PubMed ID: 34705571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
